SEC Form 4/A · accession 0000904454-15-000039

Neurogene Inc. · NGNE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owners

10% Owner

10% Owner

Period of report

Mar 12, 2014

Accepted (ET)

Feb 3, 2015 · 12:05 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001404644

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2,F1	Mar 12, 2014	C	1,392,094	—	A	1,392,094	I	Johnson & Johnson Development Corporation
Common Stock^F1	Mar 12, 2014	P	272,727	$11.00	A	1,664,821	I	Johnson & Johnson Development Corporation

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A-1 Preferred Stock^F1,F2	—	Mar 12, 2014	C	255,681	D	—	—	Common Stock	255,681	I
Series A-2 Preferred Stock^F1,F2	—	Mar 12, 2014	C	170,454	D	—	—	Common Stock	170,454	I
Series B-1 Preferred Stock^F1,F2	—	Mar 12, 2014	C	293,884	D	—	—	Common Stock	293,884	I
Series B-2 Preferred Stock^F1,F2	—	Mar 12, 2014	C	292,532	D	—	—	Common Stock	292,532	I
Series C Preferred Stock^F1,F2	—	Mar 12, 2014	C	379,543	D	—	—	Common Stock	379,543	I

F1The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
F2Upon the closing of the Issuer's initial public offering each outstanding share of Preferred Stock automatically converted into Common Stock, on a 1-to-1 basis, for no additional consideration. There was no expiration applicable to the Preferred Stock.